SXULTRASONIC
Shaping The Future: Sxultrasonic’s R&D Approach Sets The Pace

Founded as a Class II medical device manufacturer, SXULTRASONIC has witnessed a remarkable transformation over the past decade. Evolving from a domestic producer of China Food and Drugs Administration (CFDA) approved products (Class II therapeutic ultrasound for stroke, carotid artery stenosis and coronary heart disease adjuvant therapy), it is now a global player in the research, development, and manufacturing of high-performance ultrasound equipment and medical devices.

Headquartered in Shenzhen, a renowned technology and innovation hub, SXULTRASONIC is on a mission to explore the vast potential of ultrasound as a treatment modality for human diseases. Through relentless research and development (R&D), stringent quality control, and a commitment to scientific openness and flexibility, the company adapts to diverse applications of the ever-evolving clinical research domain with unmatched customizability.
“Going beyond offering ultrasound equipment and solutions, we’re here to collaborate and create excellence by co-developing innovative technology using our robust in-house R&D and quality control,” says Stephen Choi, president of SXULTRASONIC.

Responding to Personalized Medicine Demands

The drug development process is often lengthy, costly and complex, especially considering the limitations of animal models in early-stage studies. Traditionally, small animal research relied heavily on surgical procedures and postmortem histological analysis, with noninvasive imaging techniques like optical imaging, computed tomography, magnetic resonance, micro-PET-SPECT, and ultrasound reserved for later-stage studies.

This paradigm has shifted in recent years, with novel ultrasound technologies broadening the scope of noninvasive imaging applications and offering new insights and possibilities for using animal models for scientific and clinical investigation.

Sharing vast industry expertise, along with affordable, integrated and highly customized ultrasonic technology, SXULTRASONIC is a frontrunner in the creation of innovative solutions that bridge the gap between preclinical research and clinical trials. Since 2015, it has co-developed microbubbles and nanobubbles to enhance the efficiency of ultrasound-targeted microbubble destruction (UTMD), ultrasound transfection, sonodynamic therapy, and drug delivery (for in-vitro, ex-vitro, and in-vivo experiments) with renowned chemistry, nanobiotechnology and synthetic biology laboratories.

SXULTRASONIC’s powerful technology portfolio drives these successes. One of its most impactful offerings is the LIPUSTIM® 300 Series Sonodynamic Therapy System (LIPUS - low-intensity pulsed ultrasound, STIM - stimulator), an all-encompassing, low-intensity, pulsed ultrasound solution tailored for scientific research and experiments. The system comprises a built-in generator, a compensating amplifier, and a range of transducers suitable for in-vivo, ex-vivo and in-vitro studies.

LIPUSTIM® can support drug and gene delivery, cancer treatment, tissue recovery, and osteoarthritic cartilage regeneration research. With 144 standard combinations of frequency and intensity settings, the tool empowers researchers to systematically fine-tune sonodynamic therapy (SDT), making it a promising modality for discovering impactful treatments.

Playing just as important a role in reshaping ultrasound-related research is SXULTRASONIC’s Sonovitro® (Sono - ultrasound, vitro - outside the body), which aims to familiarize researchers with ultrasonic targeted drug delivery (UTMD) technology, enabling them to efficiently design, explore, and innovate with new physical materials and biological agents to streamline their fusion gene detection research. It aligns with current trends and directions to facilitate cutting-edge experiments and breakthroughs.

These developments are paving the way to explore the seemingly unlimited possibilities of ultrasound technology across the drug delivery space, garnering interest from the global scientific community. More than 93 laboratories worldwide have adopted and rigorously tested SXULTRASONIC’s ultrasound solutions. Many of these labs have published their findings in prestigious medical journals such as Elsevier, Nano and the Journal of the American Chemical Society (JACS).
Pioneering a Therapeutic Ultrasound Ecosystem

SXULTRASONIC specializes in therapeutic ultrasound, particularly low-intensity ultrasound, as a versatile and foundational technology with boundless potential to improve circulation, relieve pain and promote tissue healing. These devices can also enhance fracture rehabilitation and expedite bone growth, making it a valuable asset in physical therapy.

For over 70 years, ultrasound therapy has been a trusted choice for doctors and therapists and remains a prominent physiotherapy option for treating sports-related and soft-tissue injuries. Its use is primarily confined to clinical and professional settings today.
“There is a compelling case for making ultrasound therapy accessible to a broader spectrum of users, given its safety, efficacy and user-friendly nature,” states Choi. “To achieve this, comprehensive instructions and a solid clinical foundation on using the technology should be made available, allowing individuals to independently address common physical pain symptoms.”

SXULTRASONIC’s Sonicthera® (sonic - sound waves, thera - physical therapy) is an intelligent device designed to popularize simple, practical and effective physical therapy technology within home and work environments, allowing the general public to cope with and relieve everyday pain symptoms. The app-controlled portable device and platform enables users to acquire essential information on ultrasound and how to perform therapy sessions with ease. Sonicthera® made its debut in Edinburgh, Scotland in 2016 and Stephen Choi received the Runner-up Reward of Create in Edinburgh Competition 2016 from Donald Wilson, the Mayor of Edinburgh back then. In 2017, Choi was invited by the city council of Edinburgh and Mayor Frank Ross to be the keynote speaker of the Edinburgh-Shenzhen Creative Exchange event and exhibit Sonicthera in Ocean Terminal in Edinburgh during Edinburgh-Shenzhen Smart Innovation Week.

The underlying mission driving Sonicthera® is making therapeutic ultrasound a neutral and indispensable tool for various use cases to advance its scientific understanding and spark new applications across multiple domains.

Combining Client-Centric R&D with Expert Teams

Customization is at the heart of SXULTRASONIC’s operations. With a renowned supply chain system that ensures the consistent availability of critical components and a team characterized by their hard work, it helps identify the precise parameters and environmental conditions required for research.

Before crafting highly tailored offerings, SXULTRASONIC’s team engages in extensive consultations with clients and researchers, understands their evolving ideas, and works collaboratively to broaden the device’s applications. This fuels innovation that results in new therapeutic implementations.

There Is A Compelling Case For Making Ultrasound Therapy Accessible To A Broader Spectrum Of Users, Given Its Safety, Efficacy, And User-Friendly Nature

In a strategic move to push the industry forward, SXULTRASONIC is actively pursuing the establishment of an overseas business entity, considering Canada and Australia as probable locations for expansion. It is anticipating more subsidiaries worldwide in the near future. This forward-looking plan reflects SXULTRASONIC’s mission to reach new clients globally, foster international collaborations and expand its presence.
Choi’s profound connection to Canada, having graduated with a double major in psychology and economics from the University of Western Ontario ignited a genuine interest in the inner workings of the medical and healthcare industry. His passion eventually led to and continues to be the driver of SXULTRASONIC.

Currently, the company is engaging with distinguished universities in Hong Kong and Australia, each representing a cluster of laboratories with a keen interest in SXULTRASONIC’s groundbreaking ultrasound solutions. To provide comprehensive support for these endeavors and fortify its position in this market, the plan is to develop an R&D facility in the region.

Its team is deeply committed to the long-term growth of the company and, by extension, the broader scientific community. This journey is one of progress, innovation and dedication. SXULTRASONIC is poised to continue empowering researchers and scientists with the best in therapeutic ultrasound technology.